Laurion Capital Management’s 10x Genomics TXG Stock Holding History

Laurion Capital Management’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-8,495	Closed	-$646K	–	704
2022 Q1	$646K	Sell	8,495 -6,300	-43%	-$551K	0.01%	281
2021 Q4	$2.2M	Buy	14,795 +6,300	+74%	+$965K	0.02%	267
2021 Q3	$1.24M	Hold	8,495	–	–	0.01%	496
2021 Q2	$1.66M	Buy	+8,495	New	+$1.54M	0.01%	383
2021 Q1	–	Sell	-34,042	Closed	-$4.82M	–	899
2020 Q4	$4.82M	Buy	34,042 +24,042	+240%	+$3.49M	0.04%	256
2020 Q3	$1.25M	Buy	+10,000	New	+$1.05M	0.01%	371
2019 Q4	–	Sell	-15,000	Closed	-$756K	–	1245
2019 Q3	$756K	Buy	+15,000	New	+$830K	0.01%	692

Other funds holding TXG

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

SIM

SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return

GIM

Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

Laurion Capital Management's TXG Position: Q2 2022 in Review

Laurion Capital Management sold out of 10x Genomics (TXG) in Q2 2022, closing a stake of 8,495 shares — an estimated $646K sold.

Laurion Capital Management first reported a position in TXG in Q3 2019 and held it in 7 quarters. The position peaked at $4.82M in Q4 2020. 254 funds tracked by Wall St. Rank hold TXG as of Q2 2022.

Laurion Capital Management reported no remaining 10x Genomics position as of Q2 2022 after selling out during the quarter.
Laurion Capital Management sold 8,495 10x Genomics shares in Q2 2022, an estimated $646K.
Laurion Capital Management first reported a position in 10x Genomics in Q3 2019 and held it in 7 quarters.
Laurion Capital Management's 10x Genomics position peaked at $4.82M in Q4 2020.
254 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2022.

Based on Laurion Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.